ChloraSolv receives CE marking and is cleared for commercial launch in EU
Gothenburg, Sweden, April 10th, 2019 – RLS Global AB announces that ChloraSolv, its wound care product targeting diabetic foot ulcers, has successfully obtained a CE marking based on confirmation from Lloyd’s Register, acting as Notified Body, and is therefore cleared in 32 European countries for commercialization.
ChloraSolv is based on a Swedish innovation, which utilizes RLS Global’s proprietary buffered hypochlorite technology to debride and clean wounds to support the natural wound healing process. Clinical data has shown that ChloraSolv has unique properties with regards to cleansing infected diabetic foot ulcers, hence allowing for a more effective healing process.
“We are pleased to receive a positive confirmation from Lloyd’s register that ChloraSolv satisfies all required technological requirements.” says Karin Fischer, CEO of RLS Global. “We are now authorized to start commercialization of ChloraSolv in all 32 countries in the EU and we are very excited to bring ChloraSolv to patients suffering from diabetic foot ulcers.”
In Europe, almost four million patients are treated for diabetes-related foot ulcers every year. There is a significant unmet medical need for new, effective treatments. Chronic wounds often take a long time to heal, or do not heal at all. The incidence of diabetic foot ulcers continues to grow in line with the increasing prevalence of diabetes across Europe and the world.
“Effective cleaning and debridement ensure better conditions for wound healing,” adds Anders Husmark, Chief Business Development Officer of RLS Global. “With ChloraSolv, we can contribute toward better treatment for patients and cost efficiency for providers.”
For more information, please contact:
Karin Fischer, CEO RLS Global AB,
+46 (0)702 48 46 51, karin.fischer@rlsglobal.se
Anders Husmark, CBDO RLS Global AB,
+46 (0)72 450 94 03, anders.husmark@rlsglobal.se
PUBLICATION
This information is information that RLS Global AB (public) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10thof April, 2019, at 08:00.
| About RLS Global For more than 20 years, RLS Global has worked with oral care specialists, pioneering new therapies for oral care patients. We have now taken another major step toward easier and more effective wound care. We will continue to work with healthcare professionals to develop treatment that helps deliver the best care for each patient. The method is clinically proven and saves the patient a great deal of suffering. Our focus is on caring for patients, developing safe and efficient products that offer gentle treatment methods. We are proud to provide minimally invasive therapy, improving quality of life for patients worldwide. Certified Adviser is Erik Penser Bank, telephone +46 8 463 83 00, Email: certifiedadviser@penser.se. Read more at www.rls.global |
RLS Global is a Swedish MedTech company based in Gothenburg, founded in 1996. Through our advanced and unique Buffered Hypochlorite Technology Platform we focus on developing products based on Gentle methods for Minimally Invasive Treatment.